Monoclonal antibody therapeutics: Leading companies to maximise sales and market share

Journal of Commercial Biotechnology

Volumn 14, Issue 1, 2008, Pages 65-72

  Ziegelbauer, Karl ^a   Light, David R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION; DRUG PRODUCTS; SALES; SOCIETIES AND INSTITUTIONS;

MOLECULE DRUGS; PHARMACOLOGY; THERAPEUTIC AGENTS;

MONOCLONAL ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CHIMERIC ANTIBODY; CYCLOSPORIN; ESTROGEN; FC RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOPHILIN; INFLIXIMAB; INSULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; NATALIZUMAB; PALIVIZUMAB; PHOSPHODIESTERASE V; PROGESTERONE; PROTEIN TYROSINE KINASE; RANIBIZUMAB; RECOMBINANT HUMAN INSULIN; RITUXIMAB; TACROLIMUS; THYMIDINE KINASE; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; COMMERCIAL PHENOMENA; COMPETITION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG USE; ECONOMIC EVALUATION; HUMAN; IMMUNOTHERAPY; PROSPECTIVE PRICING; RELIABILITY; SPECIES DIFFERENCE;

EID: 37749030774     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3050081     Document Type: Article

References (12)

1. Fuh, G. (2007). Synthetic antibodies as therapeutics. Expert. Opin. Biol. Ther. 7(1), 73-87.
2. Garcia-Rodriguez, C., Levy, R., Arndt, J. W., Forsyth, C. M., Razai, A., Lou, J., Geren, I., Stevens, R. C. & Marks, J. D. (2007). Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 25(1), 107-116.
3. While the application of the clinical candidate TNX-355 (Genentech/ Tanox) is to block HIV infections, the epitope is not on the HIV virus itself, but on human CD4, a receptor that facilitates entry into target cells.
4. Baker, M. (2005). Upping the ante on antibodies. Nat. Biotechnol. 23(9), 1065-1072.
5. Wiles, M. & Andreassen, P. (2006). Monoclonals - The billion dollar molecules of the future. Drug. Disc. World 7(4), 17-23.
6. Jarvis, L. M. (2007). Biotechs rely on old products. Chem. Eng. News. 85(34), 34-35.
7. Carter, P. J. (2006). Potent antibody therapeutics by design. Nat. Rev. Immunol. 6(5), 343-357.
8. Duff, G. W., Lechler, R., Borysiewicz, L., Inglis, S., Parry, V., Walport, M., Markham, A. Haites, N., McMichael, A., Hepple, B., Piromohamed, M., Loewer, J., Klareskog, L., Park, K. & Waldmann, H. (2006). Final report of the Expert Scientific Group (ESG) on phase one clinical trials. The Stationary Shop (www.tsoshop.co.uk).
9. Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y, Dilger, P., Liefooghe, E., Cludts, I., Fox, B.,Tarrant, G., Robinson, J., Meager, T., Dolman, C., Thorpe, S. J., Bristow, A., Wadhwa, M., Thorpe, R. & Poole, S. (2007). "Cytokine Storm" in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179(5), 3325-3331.
10. Schwartzman, S. & Morgan, G.J. (2004). Does route of administration affect the outcome of TNF antagonist therapy. Arthritis. Res. Ther. 6(Suppl 2), S19-S23.
11. Schrag, D. (2004). The price tag on progress - Chemotherapy for colorectal cancer. N. Engl. J. Med. 351(4), 317-319.
12. Hawkes, N. (2006). Patients angered as watchdog refuses to allow bowel cancer drugs on NHS. The Times, 21 August.